Long‐term survival and association of neoadjuvant chemotherapy with or without immunotherapy in resectable esophageal squamous cell carcinoma

Podobne zapisy

• Neoadjuvant chemotherapy, chemoradiotherapy and immunochemotherapy followed by surgery in esophageal squamous cell carcinoma patients
  od: Ji’an Zou, BS, i wsp.
  Wydane: (2025-10-01)
• Neoadjuvant Sintilimab Plus Chemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
  od: Huilai Lv, i wsp.
  Wydane: (2022-04-01)
• Comparison of neoadjuvant chemotherapy or chemoradiotherapy plus immunotherapy for locally resectable esophageal squamous cell carcinoma
  od: Guozhen Yang, i wsp.
  Wydane: (2024-05-01)
• Predicting the Efficacy of Neoadjuvant Chemotherapy Combined with Immunotherapy for Esophageal Squamous Cell Carcinoma via Enhanced CT Radiomics Combined with Clinical Features
  od: Xiang Qin MS, i wsp.
  Wydane: (2025-08-01)
• Long-term outcome of neoadjuvant tislelizumab plus chemotherapy in locally advanced esophageal squamous cell carcinoma
  od: Hao Yin, i wsp.
  Wydane: (2025-12-01)